Key result
Surface biofunctionalization of tissue-engineered biological heart valves offers a strategy to eliminate adverse clinical reactions after implantation, though many challenges remain.
Why the study?
Clinically applied mechanical and biological heart valves have defects such as thrombosis and calcific decay, prompting the development of tissue-engineered heart valves using surface biofunctionalization to improve outcomes.
This review summarizes surface biofunctionalization strategies for tissue-engineered biological heart valves to improve upon current commercial valve limitations.
Mechanical and biological valves carry ongoing thrombosis and degeneration risks; leaves open whether coated tissue-engineered valves can enable durable regeneration.
Valve replacement is the mainstay of treatment for end-stage valvular heart disease, but varying degrees of defects exist in clinically applied valve implants. A mechanical heart valve requires long-term anti-coagulation, but the formation of blood clots is still inevitable. A biological heart valve eventually decays following calcification due to glutaraldehyde cross-linking toxicity and a lack of regenerative capacity. The goal of tissue-engineered heart valves is to replace normal heart valves and overcome the shortcomings of heart valve replacement commonly used in clinical practice. Surface biofunctionalization has been widely used in various fields of research to achieve functionalization and optimize mechanical properties. It has been applied to the study of tissue engineering in recent years. It is proposed to improve the shortcomings of the current commercial valve, but it still faces many challenges. This review aimed to summarize the modification strategies of biofunctionalization of biological heart valve surfaces based on tissue engineering to eliminate adverse reactions that occur clinically after implantation. Finally, we also proposed the current challenges and possible directions for future research.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2022) conducted a review in End-stage valvular heart disease. Surface biofunctionalization of tissue-engineered biological heart valves was evaluated. Surface biofunctionalization of tissue-engineered biological heart valves offers a strategy to eliminate adverse clinical reactions after implantation, though many challenges remain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: